U.S. drug prices are costing us more than we think

Aduhelm, the first new Alzheimer’s drug in 18 years, could easily become the best-selling drug in Medicare, despite its potential massive cost and tremendous uncertainty about whether the drug even works, says Rachel Sachs, the Treiman Professor of Law and nationally renowned expert on drug pricing and health policy. Biogen, which created the drug, halted its Aduhelm clinical trials in 2019 when an examination of early trial data suggested that the drug did not work.

Read the source article at The Source
2021-11-30 22:41:23